Cargando…
CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis
The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957656/ https://www.ncbi.nlm.nih.gov/pubmed/33804319 http://dx.doi.org/10.3390/jcm10050936 |
_version_ | 1783664699111374848 |
---|---|
author | Pépin, Jean-Louis Bailly, Sébastien Rinder, Pierre Adler, Dan Szeftel, Daniel Malhotra, Atul Cistulli, Peter A. Benjafield, Adam Lavergne, Florent Josseran, Anne Tamisier, Renaud Hornus, Pierre |
author_facet | Pépin, Jean-Louis Bailly, Sébastien Rinder, Pierre Adler, Dan Szeftel, Daniel Malhotra, Atul Cistulli, Peter A. Benjafield, Adam Lavergne, Florent Josseran, Anne Tamisier, Renaud Hornus, Pierre |
author_sort | Pépin, Jean-Louis |
collection | PubMed |
description | The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French national health insurance reimbursement system data for new CPAP users aged ≥18 years were analyzed. Innovative algorithms were used to determine the presence of specific comorbidities (hypertension, diabetes and chronic obstructive pulmonary disease (COPD)). Therapy termination was defined as cessation of CPAP reimbursements. A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male). An amount of 50.7, 24.4 and 4.3% of patients, respectively, had hypertension, diabetes and COPD. Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively. On multivariable analysis, age categories, female sex (1.09 (1.08–1.10) and COPD (1.12 (1.10–1.13)) and diabetes (1.18 (1.16–1.19)) were significantly associated with higher CPAP termination risk; patients with hypertension were more likely to continue using CPAP (hazard ratio 0.96 (95% confidence interval 0.95–0.97)). Therapy termination rates were highest in younger or older patients with ≥1 comorbidity. Comorbidities have an important influence on long-term CPAP continuation in patients with OSA. |
format | Online Article Text |
id | pubmed-7957656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79576562021-03-16 CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis Pépin, Jean-Louis Bailly, Sébastien Rinder, Pierre Adler, Dan Szeftel, Daniel Malhotra, Atul Cistulli, Peter A. Benjafield, Adam Lavergne, Florent Josseran, Anne Tamisier, Renaud Hornus, Pierre J Clin Med Article The nationwide claims data lake for sleep apnoea (ALASKA)—real-life data for understanding and increasing obstructive sleep apnea (OSA) quality of care study—investigated long-term continuous positive airway pressure (CPAP) termination rates, focusing on the contribution of comorbidities. The French national health insurance reimbursement system data for new CPAP users aged ≥18 years were analyzed. Innovative algorithms were used to determine the presence of specific comorbidities (hypertension, diabetes and chronic obstructive pulmonary disease (COPD)). Therapy termination was defined as cessation of CPAP reimbursements. A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male). An amount of 50.7, 24.4 and 4.3% of patients, respectively, had hypertension, diabetes and COPD. Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively. On multivariable analysis, age categories, female sex (1.09 (1.08–1.10) and COPD (1.12 (1.10–1.13)) and diabetes (1.18 (1.16–1.19)) were significantly associated with higher CPAP termination risk; patients with hypertension were more likely to continue using CPAP (hazard ratio 0.96 (95% confidence interval 0.95–0.97)). Therapy termination rates were highest in younger or older patients with ≥1 comorbidity. Comorbidities have an important influence on long-term CPAP continuation in patients with OSA. MDPI 2021-03-01 /pmc/articles/PMC7957656/ /pubmed/33804319 http://dx.doi.org/10.3390/jcm10050936 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pépin, Jean-Louis Bailly, Sébastien Rinder, Pierre Adler, Dan Szeftel, Daniel Malhotra, Atul Cistulli, Peter A. Benjafield, Adam Lavergne, Florent Josseran, Anne Tamisier, Renaud Hornus, Pierre CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis |
title | CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis |
title_full | CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis |
title_fullStr | CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis |
title_full_unstemmed | CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis |
title_short | CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis |
title_sort | cpap therapy termination rates by osa phenotype: a french nationwide database analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957656/ https://www.ncbi.nlm.nih.gov/pubmed/33804319 http://dx.doi.org/10.3390/jcm10050936 |
work_keys_str_mv | AT pepinjeanlouis cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT baillysebastien cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT rinderpierre cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT adlerdan cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT szefteldaniel cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT malhotraatul cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT cistullipetera cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT benjafieldadam cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT lavergneflorent cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT josserananne cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT tamisierrenaud cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT hornuspierre cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis AT cpaptherapyterminationratesbyosaphenotypeafrenchnationwidedatabaseanalysis |